Oracle Investment Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Oracle Investment Management’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-80,000	Closed	-$2.17M	–	52
2021 Q3	$2.17M	Buy	+80,000	New	+$9.99M	0.27%	22
2021 Q1	–	Sell	-100,000	Closed	-$400K	–	33
2020 Q4	$400K	Buy	100,000 +31,900	+47%	+$2.7M	0.05%	21
2020 Q3	$423K	Buy	68,100 +5,000	+8%	+$328K	0.06%	18
2020 Q2	$2.49M	Sell	63,100 -36,900	-37%	-$1.96M	0.32%	14
2020 Q1	$218K	Buy	+100,000	New	+$4.57M	0.06%	17
2019 Q4	–	Sell	-596,000	Closed	-$966K	–	22
2019 Q3	$966K	Buy	596,000 +137,200	+30%	+$5.8M	0.24%	16
2019 Q2	$692K	Sell	458,800 -280,200	-38%	-$15.8M	0.15%	17
2019 Q1	$3.42M	Buy	+739,000	New	+$31.9M	0.73%	13

Other funds holding BHVN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SFM

Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Oracle Investment Management's BHVN Position: Q3 2022 in Review

Oracle Investment Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2022, closing a stake of 1,240,932 shares — an estimated $181M sold.

Oracle Investment Management first reported a position in BHVN in Q4 2018 and held it in 15 quarters. The position peaked at $295M in Q3 2021. 240 funds tracked by Wall St. Rank hold BHVN as of Q3 2022.

Oracle Investment Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2022 after selling out during the quarter.
Oracle Investment Management sold 1,240,932 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2022, an estimated $181M.
Oracle Investment Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2018 and held it in 15 quarters.
Oracle Investment Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $295M in Q3 2021.
240 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2022.

Based on Oracle Investment Management's 13F filing for Q3 2022, filed 14 Nov 2022.